Monthly
US$200
Billed every month
Levonorgestrel Tablets(左炔诺孕酮片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 1 applicationSupplement delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders8View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers19View records ↓
API companies with A status7View records ↓
Chemical-drug catalogue
Loaded records: 8 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 4 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 广州朗圣药业有限公司 | 广州朗圣药业有限公司 | 国药准字H20254398 | 2025/05/27 | 1.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| EXELTIS HEALTHCARE S.L. | LABORATORIOS LEON FARMA, S.A. | 国药准字HJ20240161 | 2024/12/06 | 1.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东北制药集团沈阳第一制药有限公司 | 东北制药集团沈阳第一制药有限公司 | 国药准字H19983177 | 2022/09/13 | 0.75mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 东北制药集团沈阳第一制药有限公司 | 东北制药集团沈阳第一制药有限公司 | 国药准字H20058582 | 2022/09/13 | 1.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 华润紫竹药业有限公司 | 华润紫竹药业有限公司 | 国药准字H10983129 | 2022/08/03 | 0.75mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 华润紫竹药业有限公司 | 华润紫竹药业有限公司 | 国药准字H11021372 | 2022/08/03 | 1.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南通联亚药业有限公司 | 南通联亚药业有限公司 | 国药准字H20223038 | 2022/01/30 | 1.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海信谊天平药业有限公司 | 上海信谊天平药业有限公司 | 国药准字H20163176 | 2020/09/08 | 1.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 上海信谊天平药业有限公司 | 上海信谊天平药业有限公司 | 国药准字H20093259 | 2020/09/08 | 0.75mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| Gedeon Richter Plc. | Gedeon Richter Plc. | H20140728 | 2009/12/24 | 1.5 mg | Imported originator drug (进口原研药品) | CDE |
| Gedeon Richter Plc. | Gedeon Richter Plc. | H20140053 | 2000/04/26 | 0.75 mg | Imported originator drug (进口原研药品) | CDE |
| 武汉九珑人福药业有限责任公司 | 武汉九珑人福药业有限责任公司 | 国药准字H20255422 | 2025/09/09 | 1.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 19 distinct approval numbers and 14 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京利龄恒泰药业有限公司 | 国药准字H19983072 | 0.75mg | Not stated by source | XG03ADZ061A001010100088 | NHSA |
| 北京富亚东投资管理有限公司 | 国药准字H20184076 | 0.75mg | Not stated by source | XG03ADZ061A001010100200 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H10983129 | 0.75mg | Not stated by source | XG03ADZ061A001010100225 | NHSA |
| 上海信谊天平药业有限公司 | 国药准字H20163176 | 1.5mg | Not stated by source | XG03ADZ061A001010100800 | NHSA |
| 上海信谊天平药业有限公司 | 国药准字H20093259 | 0.75mg | Not stated by source | XG03ADZ061A001010100803 | NHSA |
| 东北制药集团沈阳第一制药有限公司 | 国药准字H19983177 | 0.75mg | Not stated by source | XG03ADZ061A001010101161 | NHSA |
| 华中药业股份有限公司 | 国药准字H20023296 | 0.75mg | Not stated by source | XG03ADZ061A001010101884 | NHSA |
| 四川川大华西药业股份有限公司 | 国药准字H20113212 | 0.75mg | Not stated by source | XG03ADZ061A001010102129 | NHSA |
| 广州朗圣药业有限公司 | 国药准字H20254398 | 1.5mg | Not stated by source | XG03ADZ061A001010107360 | NHSA |
| 北京法莫斯达制药科技有限公司 | 国药准字H20133081 | 1.5mg | Not stated by source | XG03ADZ061A001010107599 | NHSA |
| Gedeon Richter Plc. | 国药准字HJ20140728 | 1.5mg | Not stated by source | XG03ADZ061A001010179164 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20184036 | 0.75mg | Not stated by source | XG03ADZ061A001010180465 | NHSA |
| 武汉九珑人福药业有限责任公司 | 国药准字H20255422 | 1.5mg | Not stated by source | XG03ADZ061A001010183319 | NHSA |
| 南通联亚药业股份有限公司 | 国药准字H20223038 | 1.5 mg | Not stated by source | XG03ADZ061A001010183802 | NHSA |
| Maxmind Pharmaceutical GmbH | 国药准字HJ20240161 | 1.5mg | Not stated by source | XG03ADZ061A001010185381 | NHSA |
| 北京利龄恒泰药业有限公司 | 国药准字H19983072 | 0.75mg | Not stated by source | XG03ADZ061A001010200088 | NHSA |
| 上海信谊天平药业有限公司 | 国药准字H20093259 | 0.75mg | Not stated by source | XG03ADZ061A001010200803 | NHSA |
| 华中药业股份有限公司 | 国药准字H20023296 | 0.75mg | Not stated by source | XG03ADZ061A001010201884 | NHSA |
| 四川川大华西药业股份有限公司 | 国药准字H20113212 | 0.75mg | Not stated by source | XG03ADZ061A001010202129 | NHSA |
| 广州朗圣药业有限公司 | 国药准字H20254398 | 1.5mg | Not stated by source | XG03ADZ061A001010207360 | NHSA |
| 北京法莫斯达制药科技有限公司 | 国药准字H20133081 | 1.5mg | Not stated by source | XG03ADZ061A001010207599 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20184036 | 0.75mg | Not stated by source | XG03ADZ061A001010280465 | NHSA |
| 北京利龄恒泰药业有限公司 | 国药准字H20103026 | 1.5mg | Not stated by source | XG03ADZ061A001020100088 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H11021372 | 1.5mg | Not stated by source | XG03ADZ061A001020100225 | NHSA |
| 东北制药集团沈阳第一制药有限公司 | 国药准字H20058582 | 1.5mg | Not stated by source | XG03ADZ061A001020101161 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20184035 | 1.5mg | Not stated by source | XG03ADZ061A001020180465 | NHSA |
| 北京利龄恒泰药业有限公司 | 国药准字H20103026 | 1.5mg | Not stated by source | XG03ADZ061A001020200088 | NHSA |
| 东北制药集团沈阳第一制药有限公司 | 国药准字H20058582 | 1.5mg | Not stated by source | XG03ADZ061A001020201161 | NHSA |
| 山东鑫惠药业有限公司 | 国药准字H20184035 | 1.5mg | Not stated by source | XG03ADZ061A001020280465 | NHSA |
| 华润紫竹药业有限公司 | 国药准字H11021372 | 1.5mg | Not stated by source | XG03ADZ061A001020300225 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 3 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 株洲千金药业股份有限公司;北京法莫斯达制药科技有限公司 | CYHS2600047 | Generic | 2026/01/06 | Not stated by source | CDE |
| 浙江爱生药业有限公司 | CYHS2600035 | Generic | 2026/01/06 | Not stated by source | CDE |
| 湖南醇健制药科技有限公司;北京法莫斯达制药科技有限公司 | CYHS2504100 | Generic | 2025/11/28 | Not stated by source | CDE |
| 湖南醇健制药科技有限公司;北京法莫斯达制药科技有限公司 | CYHS2504099 | Generic | 2025/11/28 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 7 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 左炔诺孕酮 | 江苏联环药业股份有限公司 | Y20190009601 | A | Exact ingredient | 2025/07/18 | CDE |
| 左炔诺孕酮 | 湖南科益新生物医药有限公司 | Y20220000428 | A | Exact ingredient | 2026/01/17 | CDE |
| 左炔诺孕酮 | INDUSTRIALE CHIMICA SRL | Y20190000943 | A | Exact ingredient | 2025/01/28 | CDE |
| 左炔诺孕酮 | 北京市科益丰生物技术发展有限公司 | Y20190009473 | A | Exact ingredient | — | CDE |
| 左炔诺孕酮 | 湖北葛店人福药业有限责任公司 | Y20190007482 | A | Exact ingredient | 2026/07/08 | CDE |
| 左炔诺孕酮 | 秦皇岛紫竹药业有限公司 | Y20190003154 | A | Exact ingredient | 2026/09/29 | CDE |
| 左炔诺孕酮 | 华中药业股份有限公司 | Y20190003122 | A | Exact ingredient | 2025/06/11 | CDE |
| 左炔诺孕酮 | 扬州制药有限公司 | Y20190000403 | I | Exact ingredient | 2019/05/28 | CDE |
| 左炔诺孕酮 | 北京市科益丰生物技术发展有限公司 | Y20170002309 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/06No longer listed under review
Gedeon Richter Plc.
JYHB2600275
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2026/05/14
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/04Supplement delivery
吉瑞医药（中国）有限公司
JYHB2600275
Fact date: 2026/11/04 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 194 ↗ -
2026/09/02Accepted
Gedeon Richter Plc.
JYHB2600507
Fact date: 2026/09/02 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Levonorgestrel Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy